Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - Public Policy

LBA66_PR - Disparities in access to oncology clinical trials in Europe in the period 2009-2019


21 Sep 2020


Proffered Paper - Public Policy


Bioethical Principles and GCP

Tumour Site

Neuroendocrine Neoplasms


Ana Carneiro


Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325


A. Carneiro1, T.M.S. Amaral2, M. Brandao3, M. Scheffler4, K. Bol5, R. Ferrara6, M. Jalving7, G. Lo Russo8, I. Marquez-Rodas9, A. Matikas10, L. Mezquita11, G. Morgan12, C.E. Onesti13, S. Pilotto14, E. Saloustros15, D. Trapani16

Author affiliations

  • 1 Department Of Clinical Sciences Lund, Oncology,, Lund University, Skane University Hospital, 222 41 - Lund/SE
  • 2 Dermatooncology Center, University Hospital Tubingen, 72076 - Tuebingen/DE
  • 3 Clinical Trial Support Unit, Institute Jules Bordet, 1000 - Brussels/BE
  • 4 Lung Cancer Group Cologne, Department I Of Internal Medicine, Uniklinik Köln, 50937 - Cologne/DE
  • 5 Medical Oncology Department, Herlev Hospital - National Center for Cancer Immune Therapy, 2730 - Herlev/DK
  • 6 Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 - Milan/IT
  • 7 Department Of Medical Oncology, University Medical Center Groningen, Groningen/NL
  • 8 Dipartimento Oncologia Toraco-polmonare, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, 20133 - Milan/IT
  • 9 Medical Oncology, Hospital General Universitario Gregorio Marañon - Fundación Investigación Biomedica, 28009 - Madrid/ES
  • 10 Oncology-pathology Department, Karolinska University Hospital-Solna, 17176 - Stockholm/SE
  • 11 Medical Oncology Department, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES
  • 12 Oncology, Skane University Hospital, 222 41 - Lund/SE
  • 13 Medical Oncology Department, Centre Hospitalier Universitaire Sart Tilman, 4000 - Liège/BE
  • 14 Section Of Oncology, Department Of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, 37134 - Verona/IT
  • 15 Department Of Oncology, University Hospital of Larissa, 411 10 - Larissa/GR
  • 16 Irccs, Istituto Europeo di Oncologia, 20141 - Milan/IT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract LBA66_PR


Clinical trials are essential for advancing cancer treatment. Yet, there is limited data on their distribution and access in Europe. To ascertain the extent of potential inequalities in access to clinical trials in Europe, we compared their distribution among European countries.


The Clinicaltrials.gov database was searched for interventional clinical trials in adults with neoplasms. Available data from phase I-III trials between 06/2009 to 06/2019 in Europe were retrieved. We considered the number of clinical trials registered in each country and one “trial-entry” was defined as one trial/country.


In total, 18454 trial-entries were identified, of which 12% were phase I, 10% phase I/II, 32% phase II, 2% phase II/III and 44% phase III; 74% were industry-sponsored, 15% were academic and 11% were an academic/industry partnership. The number of trials per country varied from 2.48 in Central/Eastern Europe to 5.33/100 000 inhabitants in Northern Europe. The proportion of phase I-II trials was higher in the Southern and Western regions (13-15%) compared to Central/Eastern and Northern regions (4-9%). The number of trial-entries/100 000 inhabitants/country ranged from 0.14 (Albania) to 10.7 (Belgium). Between 2010 and 2018, the total number of trials per country in Europe increased by 33%. The increase in early-phase trials was larger (phase I-II, 61%) than in late-phase trials (phase II-III, 7%). Portugal, Ireland, Finland, Greece and Norway registered the largest percentage increase in early-phase trials, while Ireland, Spain, Norway, Italy and Belgium led the largest percentage increase in late-phase trials. Five countries dominated in terms of an increase in the absolute number of total trial-entries in both early- and late-phase trials: Spain (90/40), France (45/16), UK (45/13), Italy (38/19) and Belgium (35/12). During this period there was no significant variation in the distribution of industry and academic sponsored trials but an increase in industry/academic partnerships was observed (≈ 8%).


The number of clinical trials varies greatly among European regions resulting in potential asymmetries in patients' access to clinical trials. The disparities in access to oncology trials need to be addressed by all the stakeholders.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


T.M.S. Amaral: Honoraria (self), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Travel/Accommodation/Expenses: BMS; Honoraria (self): Pierre Fabre; Honoraria (self): CeCaVa. M. Brandao: Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche/GNE. M. Scheffler: Advisory/Consultancy, Speaker Bureau/Expert testimony: Boehringer Ingelheim, Amgen, AstraZeneca, BMS, Roche, Pfizer, Takeda; Research grant/Funding (self): Amgen, Dracen. R. Ferrara: Advisory/Consultancy: MSD. M. Jalving: Advisory/Consultancy: Merck, BMS, Novartis, Pierre Fabre, Tesaro, AstraZeneca; Research grant/Funding (self): BMS, AbbVie, Merck, Cristal Therapeutics. G. Lo Russo: Advisory/Consultancy: MSD, BMS, Astrazeneca; Travel/Accommodation/Expenses: BMS, Roche. I. Marquez-Rodas: Advisory/Consultancy: BMS, MSD, Novartis, Roche, Pierre Fabre, Amgen, AstraZeneca, Regeneron, Sanofi, Highlight Therapeutics, Incyte, GSK. L. Mezquita: Research grant/Funding (self): Bristol-Myers Squibb, Boehringer Ingelheim; Non-remunerated activity/ies, Lectures and educational activities: Bristol-Myers Squibb, Tecnofarma, AstraZeneca, Roche; Advisory/Consultancy: Roche Diagnostics, Roche; Travel/Accommodation/Expenses: Bristol-Myers Squibb, Roche; Research grant/Funding (self), International Mentorship Program : AstraZeneca. S. Pilotto: Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca, Eli-Lilly, BMS, Boehringer Ingelheim, MSD and Roche. E. Saloustros: Advisory/Consultancy: Pfizer, AstraZeneca, Roche; Speaker Bureau/Expert testimony: Pfizer, AstraZeneca, Roche, Amgen, BMS. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.